Loading...
XJPX
4892
Market cap25mUSD
Jul 10, Last price  
552.00JPY
1D
2.99%
1Q
-9.06%
IPO
-75.07%
Name

Cyfuse Biomedical KK

Chart & Performance

D1W1MN
XJPX:4892 chart
P/E
P/S
18.66
EPS
Div Yield, %
Shrs. gr., 5y
4.19%
Rev. gr., 5y
10.94%
Revenues
231m
+324.27%
137,484,000708,245,000374,477,00061,112,00054,446,000230,999,000
Net income
-764m
L-12.43%
-329,501,000142,905,000-473,962,000-589,211,000-872,238,000-763,843,000
CFO
-535m
L-29.68%
-294,001,000161,537,000-403,596,000-562,296,000-760,553,000-534,793,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
IPO date
Dec 01, 2022
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT